期刊文献+

医院不发酵糖革兰阴性杆菌的耐药性调查 被引量:2

Drug-resistance of Nonfermentative Gram-negative Bacilli
原文传递
导出
摘要 目的探讨医院临床常见不发酵糖革兰阴性杆菌对抗菌药物的耐药性,为临床医师合理用药提供科学依据。方法调查医院铜绿假单胞菌(PAE)、鲍氏不动杆菌(ABA)、嗜麦芽寡养单胞菌(PMA)的分离率及耐药率。结果 388株不发酵糖革兰阴性杆菌中,PAE占44.6%;ABA占33.8%;SMA占11.1%;其他不发酵糖革兰阴性杆菌占10.6%;3种菌株对抗菌药物产生了不同程度的耐药性,且ABA对抗菌药物的耐药率已普遍高于PAE。结论不发酵糖革兰阴性杆菌的耐药性已非常严重,应采取有效措施,预防与控制多药耐药菌医院感染。 OBJECTIVE To investigate drug-resistance of commonly isolated nonfermentative Gram-negative bacilli in the First Renming Hospital of Jingzhou and offer the scientific evidence for reasonable application of antibiotics.METHODS The rates of isolation and drug-resistance of Pseudomonas aeruginosa(PAE),Acinetobacter baumannii(ABA) and Stenotrophomonas maltophilia(SMA) were investigated.RESULTS Among 388 nonfermenters,PAE accounted for 44.6%,ABA for 33.8%,SMA for 11.1% and the others for 10.6%.Drug-resistance to different degrees had occurred in three nonfermenters.The rates of drug-resistance of ABA were generally higher than those of PAE.CONCLUSIONS The drug-resistance of nonfermentative Gram-negative bacilli is very serious.The effective measures should be adopted to prevent and control the nosocomial infections with multi-resistant strains.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2010年第9期1325-1326,共2页 Chinese Journal of Nosocomiology
关键词 不发酵糖革兰阴性杆菌 医院感染 耐药性 Nonfermentative Gram-negative bacilli Nosocomial infections Drug-resistance
  • 相关文献

参考文献8

二级参考文献79

共引文献296

同被引文献17

  • 1朱焱,明德松,谢尊金.全部耐药的短稳杆菌耐药机制的初步研究[J].中华医院感染学杂志,2005,15(10):1181-1182. 被引量:6
  • 2赵松,王小文,陈惠德,李文雄,陈秀凯,郑悦,宋阳.外科ICU黄杆菌科致呼吸机相关性肺炎的危险因素及耐药性分析[J].中华医院感染学杂志,2007,17(4):391-393. 被引量:14
  • 3Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xy- losoxidans respiratory tract infection in cystic fibrosis patients [J]. Eur J Clin Microbiol Infect Dis, 2011, 30 (8): 973-980.
  • 4Hansen CR, Pressler T, Nielsen KG, et al. Inflammation in achromobacter xylosoxidans infected cystic fibrosis patients [J]. J Cyst Fibros, 2010, 9 (1): 51-58.
  • 5Raso T, Bianco O, Grosso B, et al. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients [J]. APMIS, 2008, 116 (9): 837-841.
  • 6Lambiase A,Catania MR,Del Pezzo M. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients[J].European Journal of Clinical Microbiology and Infectious Diseases,2011,(08):973-980.
  • 7Hansen CR,Pressler T,Nielsen KG. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients[J].Journal of Cystic Fibrosis,2010,(01):51-58.
  • 8Raso T,Bianco O,Grosso B. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients[J].Acta Pathologica, Microbiologica et Immunologica Scandinavica,2008,(09):837-841.
  • 9Atalay S,Ece G,Samlioglu P. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans[J].SCANDINAVIAN Journal OF INFECTIOUS DISEASES,2012,(10):798-801.
  • 10Yamamoto M,Nagao M,Hotta G. Molecular characterization of IMP-type metallo--lactamases among multidrug-resistant Achromobacter xylosoxidans[J].Journal of Antimicrobial Chemotherapy,2012,(09):2110-2113.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部